Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

2022 ProSites Manager of the Year Award Winners Announced


ProSites logo

Andrea leads by example. As a manager she has always given me plenty of support as I continue to learn my position. She’s never too busy to lend an ear or helping hand. I respect Andrea as our manager because when all else fails she’s always there for each and every one of her team members.

In late 2021, ProSites decided to create the first ever ProSites Manager of the Year Award for 2022. “With everything that office managers contribute to their dental practices 24/7/365, we felt it was time to recognize these individuals in a very tangible way for all of their hard work – especially over the past few years,” said Luke Wilson, Chief Revenue Officer at ProSites.

In appreciation and celebration of dental office managers everywhere, the ProSites Manager of the Year Award was designed to highlight the incredible impact of office managers in their practices and the dental industry as a whole.

Now that nominations for the 2022 ProSites Manager of the Year Award have officially come to a close, we are pleased to announce that this year’s award winners are:

1st Place – Andrea Tinsley from Henderson Mill Dental Care in Atlanta, GA

2nd Place – Melissa Cortes from Gentle Family Dentistry in Dunkirk, MD

3rd Place – Sonia Desai from Seawall Dental in West Vancouver, BC

Andrea and the rest of this year’s winners are prime examples of how dental office managers go above and beyond to support and care for their teams and patients.

“Andrea leads by example. As a manager she has always given me plenty of support as I continue to learn my position. She’s never too busy to lend an ear or helping hand. I respect Andrea as our manager because when all else fails she’s always there for each and every one of her team members,” said another member of the Henderson Mill Dental Care team, Renee Dobbins.

“I feel she deserves this award because she shows true integrity and exceptional leadership. We are such a blessed team to have Andrea Tinsley as our manager!”

This year’s winners were announced during the American Association of Dental Office Managers Annual Conference (Sept 8-10) in Scottsdale, AZ, at the ProSites Booth. We want to personally thank each of our nominees for their efforts to improve their practices and the lives of their team members and patients.

Nominations for the 2023 ProSites Manager of the Year Award will open in Spring 2023. Visit https://www.ProSites.com for upcoming news on 2023 nominations, and the opportunity to nominate your office manager this coming spring!

About ProSites 

ProSites delivers innovative website design and digital marketing solutions to help dental and medical professionals build patient trust and improve patient care. The ProSites comprehensive suite of solutions includes ready-to-go and custom website design, search engine marketing, social media management, automated patient communications, and pay-per-click services. ProSites is trusted by over 7,500 dental practices and endorsed by 15 state dental associations. Learn more about ProSites by visiting https://www.ProSites.com or call (888) 932-3644.

Media Inquiries 

Tiffany Isbell 

VP of Brand and Content Marketing 

ProSites 

press@prosites.com 

Share article on social media or email:

Regal Introduces Special Mold & Die Components that are Custom Manufactured & Precision Ground to ±0.000050”


News Image

Regal Special Mold & Die Components can incorporate details including tapers, rings, vents, ribs and spirals shaped using wire EDM.

Suitable for a wide range of OEM requirements, Regal Special Mold & Die Components can be precision ground to a tolerance of ±0.000050” in lengths up to 14” L with tip diameters as small as 0.002”.

If you need custom core pins, sleeves, ejectors, blades, and punches, check with Regal Components, Inc. of East Providence, RI. They precision manufacture specials for leading manufacturers, distributors, and end-users.

Regal Special Mold & Die Components can be precision ground to a tolerance of ±0.000050” in lengths up to 14” L with tip diameters as small as 0.002”. Featuring surface finishes to 2 RMS, they can be custom manufactured from tool steels such as M-2, A-2, A-10, H-13, S-7, PM-M4, PM-10V, PM-15V, 420 and 440 stainless steels, and beryllium-free copper alloys, and can be polished, coated and plated for additional wear resistance and lubricity.

Suitable for a wide range of OEM requirements, Regal Special Mold & Die Components can incorporate details including tapers, rings, vents, ribs, and spirals shaped using wire EDM. Applications include molding a variety of medical, electronics, and consumer products that require extreme precision such as needles, sheaves, closures, nipples, pipettes, IV connectors, shavers, electronic components, and writing instruments.

Regal Special Mold & Die Components are priced according to material, configuration, and quantity. Price quotations are provided upon request.

For more information contact:

Regal Components, Inc.

Derek Coelho, VP Sales

10 Almeida Ave.

East Providence, RI 02914

(727) 299-0800 FAX (727) 499-7109

Email: sales@regalcomps.com

http://www.regalcomps.com

Share article on social media or email:

YorLabs Appoints Gregory D. Casciaro to Board of Directors


This team has very successful track records in medical device markets and in developing significant technology to enhance clinical results for millions of patients.

YorLabs, a developer of cutting-edge intracardiac image guided therapy solutions, today announced the appointment of Gregory “Greg” D. Casciaro to the company’s Board of Directors. Casciaro has 40 years of medical device experience and has held leadership roles in both public and private companies.

“We are pleased to welcome Greg to the YorLabs leadership team,” said Glen McLaughlin, president and CEO, YorLabs. “His extensive experience in the medical device industry, including several cardiac therapy solutions companies, will provide superb insights and guidance in our goal of developing the next generation, intracardiac image guided therapy platform.”

Casciaro is currently the president and CEO of Foldax Inc, the maker of Tria Heart Valves. Previously, he was the CEO, president and director of Cardiac Dimensions, as well as AccessClosure, Inc., a medical device company that was acquired by Cardinal Health. He also served in similar capacities at XTENT, a medical device company acquired by Biosensors International Group, and Orquest, a private company manufacturing and selling biotherapeutic products to the orthopedic market, which was acquired by DePuy Acromed, a division of Johnson and Johnson. He has been a member of the board of directors of QT Vascular Ltd., a Singaporean-listed company engaged in the design, assembly and distribution of therapeutic solutions for the minimally invasive treatment of complex vascular diseases, since 2001. Casciaro graduated from Marquette University with a B.S. in Business Administration.

“I joined the Yorlabs board, because of the high quality team Glen has assembled,” said Casciaro. “This team has very successful track records in medical device markets and in developing significant technology to enhance clinical results for millions of patients. It is exciting to join YorLabs in its endeavors to enable excellence in patient care.”

Today’s cath lab faces numerous challenges including capital constraints and disparate systems within the interventional cardiac (IC) and Electrophysiology (EP) markets. YorLabs’ vision is to provide a comprehensive, integrated therapy imaging solution with outstanding image quality and significantly improved workflow, while offering relief from large capital outlays and enabling ongoing, state-of-the art visualization.

To this end, YorLabs is designing its solution to provide automatic upgrades to maintain cutting-edge technology throughout the lifecycle of the platform. The company is developing novel algorithms to enable world class, intracardiac image guided therapy performance with dedicated application and procedural based settings and offerings. This solution will be an intuitive user interface platform, resulting in significant clutter and size reduction along with a greatly enhanced workflow.

“Greg is well qualified to serve on our board of directors,” said Anshumali Roy, founder and chief technology officer for YorLabs. “He has extensive management experience with growth companies and in mergers and acquisitions in the medical device industry – all of which will benefit YorLabs in successfully achieving its vision.”

About YorLabs

Today’s Cath Lab faces numerous challenges including capital constraints and disparate systems. YorLabs is developing a world class, intracardiac image guided therapy platform with dedicated application and procedural based settings. The YorLabs solution is designed to be an intuitive platform while eliminating large capital outlays and significantly enhancing workflow. For further information, visit http://www.yorlabs.com.

Share article on social media or email:

Moxie Scrubs Named in Fast Company’s Second Annual List of “Brands That Matter”


Moxie Scrubs Logo

Moxie Scrubs: Designed For Nurses, By Nurses

“It is an honor to be recognized by Fast Company for our meaningful work supporting nurses across the country. I feel so grateful that I get to build this amazing brand that supports nurses where they need the support the most.” – Moxie Scrubs’ Founder and CEO, Alicia Tulsee

Fast Company announced today its second annual “BrandsThat Matter” list, honoring brands that communicate and demonstrate brand purpose. These companies and nonprofits have achieved relevance through cultural impact and social engagement, and authentically communicated their missions and ideals.

The final list, which includes large multinational conglomerates, small-but-mighty companies, and nonprofits, recognizes 145 brands that give people compelling reasons to care about them—and offer inspiration for others to buy in. All 145 have found an ability to forge an emotional connection with customers, whether leading on the environment or pop culture, engaging B2B customers, or responding meaningfully to current events.

All brands that applied were considered for overall recognition. Additionally, there are also honorees on category-specific lists based on region, size, and status.

“This year, we’ve expanded the Brands That Matter program to evaluate honorees in the context of how they matter within the category in which they compete for people’s attention or loyalty. The result is a wide-ranging list of honorees that are making their mark on culture, and through social impact,” said Brendan Vaughan, Fast Company’s editor-in-chief.

“Entrepreneurship gives you the opportunity to take your life in directions you would never think could be possible. And it’s even more beautiful when your business helps to improve the lives of millions of people across the country,” explains Moxie Scrubs’ Founder and CEO, Alicia Tulsee. “It is an honor to be recognized by Fast Company for our meaningful work supporting nurses across the country. I feel so grateful that I get to build this amazing brand that supports nurses where they need the support the most.”

The idea for Moxie Scrubs was developed in Harvard University’s Innovation Lab in 2019 when Alicia couldn’t seem to find a brand dedicated to nurses and their unique performance needs, despite nurses being the largest and fastest-growing segment of the healthcare workforce with significantly different needs compared to other roles in healthcare. This gave birth to their mission to create a lifestyle brand made by nurses for nurses where every design is named after the nurse who worked with their design team to create the scrubs they want to wear, building a strong community and inclusivity around the brand to become a beacon for nurse culture.

Less than two years later, CEO Alicia Tulsee was named on the 2021 Forbes Next 1000 List, spotlighting the dedication she had not only to building this brand, but also her continuous support of the nursing community as the COVID-19 pandemic revealed the unwavering courage of frontline heroes around the world.

By early 2022, Tulsee surpassed her goals and single-handedly raised over $2.4 million dollars in pre-seed funding for Moxie Scrubs. In the process of doing so, she found herself recognized once again, this time by ForbesWomen for her tenacity and drive to push forward through any obstacle that stood in her way of achieving the goals she set for Moxie Scrubs.

Fast Company editors judged each brand on relevancy, cultural impact, ingenuity, and business impact to compile the list.

Click here to see the complete list.

The November issue of Fast Company magazine is available online now and will be on newsstands beginning November 1, 2022.

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

About Moxie Scrubs

Born out of Harvard’s Innovation Lab, Moxie Scrubs is disrupting the medical apparel market as the first direct-to-consumer lifestyle brand for nurses, by nurses. Boston-based Moxie Scrubs was founded by Alicia Tulsee, a native New Yorker and Harvard alum. In awe of all of the amazing nurses who cared for her loved ones, Alicia felt a calling to do something meaningful for the nursing profession. ‘Moxie’ defines the ‘force of character, determination, and resourcefulness,’ of the nurses across our country on the frontlines today. More than a brand, this is a movement. For more information, visit http://www.moxiescrubs.com

Share article on social media or email:

BlueDot announces new leadership as it prepares for rapid growth in 2023


BlueDot is pleased to welcome Dr. Andrea Thomas, Jannine Krish and Les Lengyel to the leadership team.

BlueDot’s newly appointed leadership team comes at a time when the market need for infectious disease intelligence is rising, so governments and private sector organizations can make critical decisions with more agility and better insights.

BlueDot Inc., the leading artificial and human intelligence organization for detecting, assessing, and responding to global infectious diseases, announced the expansion of its executive team as it enters its next phase of growth. As part of the company’s continued work in building private and public sectors’ resiliency to outbreaks, BlueDot announced the hires of Les Lengyel, Vice President of Sales and Jannine Krish, Vice President of Marketing, in addition to the promotion of Dr. Andrea Thomas to Director of Epidemiology.

Les Lengyel is a tenured leader in the AI SaaS, Life Sciences and MedTech sectors, and brings to BlueDot a keen ability to drive significant growth having achieved revenue increases year over year and tripled purchase order growth in previous roles. With over a decade in Philips Healthcare and Roche respectively alone, he brings a critical understanding of how to drive successful key initiatives and company growth.

Jannine Krish is an experienced marketing leader with 15 years of experience in building and scaling iconic Canadian startups and enterprise brands on a global stage. Through a combination of storytelling and performance marketing, she’s led marketing strategies that build industry leadership, consumer trust and business results. Jannine has held senior marketing roles at Flybits, Union Pearson Express and Porter Airlines.

Dr. Andrea Thomas has been a predominant figure in driving excellence in epidemiology at BlueDot over the past five years. She led the data science team in introducing innovative approaches to data science throughout the pandemic and maintains academic excellence with frequent publications, including the world’s first publication on COVID-19 and a publication estimating potential global exportation of monkeypox. Dr. Thomas holds a Doctor of Veterinary Medicine degree, along with a Masters and PhD in Epidemiology.

“Our company went through a rapid phase of growth during the height of the COVID 19 pandemic,” said Dr. Kamran Khan, Founder and CEO, BlueDot. “Now as we prepare for this next phase of growth, I’m excited about deepening our pool of talented leaders to expand our global reach and impact.”

BlueDot’s newly appointed leadership team comes at a time when the market need for infectious disease intelligence is rising, so governments and private sector organizations can make critical decisions with more agility and better insights.

About BlueDot

BlueDot’s intelligence platform empowers public and private sector organizations to rapidly identify, understand, and effectively respond to global biothreats. Combining human and artificial intelligence to track hundreds of infectious diseases and syndromes worldwide, it applies academic data science expertise to anticipate global spread and impact. BlueDot ensures clients know first when disease events emerge, are prepared to respond, can focus on what matters, and can act swiftly and confidently when needed. Founded in 2013 and used by the City of Chicago, Taiwan CDC, Air Canada and more, BlueDot helps clients make critical decisions with clarity and confidence. Learn more at http://www.bluedot.global

Share article on social media or email:

HeardThat Recognized as Runner-up at AGE-WELL National Impact Challenge 2022 for Improving Intelligibility of Conversations in Loud Places for Aging Population


News Image

Singular Hearing, a subsidiary of Singular Software and creator of HeardThat, today announced it gained the runner-up distinction at the AGE-WELL National Impact Challenge 2022 for its hearing-assistive, AI-powered app. HeardThat was one of six finalists that pitched their innovation at the AGE-WELL Annual Conference, a Canadian conference discussing current issues and innovations in the field of technology and aging.

HeardThat was recognized for success in improving the health and quality of life of older adults by enhancing intelligibility and reducing listening effort for those that have trouble hearing conversations in loud places, like restaurants or social gatherings. Since its early release, HeardThat has gained thousands of regular users.

“It’s an honor to be recognized by AGE-WELL, along with the other outstanding finalists,” said Singular Hearing CEO and HeardThat Founder Bruce Sharpe. “We created HeardThat to solve a very common hearing ability challenge and empower users to hear more speech, less noise. Thank you, AGE-WELL for the accolades and an inspiring conference.”

“HeardThat’s use of artificial intelligence to help people stay socially connected really changes the game for hearing-assistive AgeTech,” said Michael Chrostowski, PhD, Senior Manager, Business Development and Industry Relations, AGE-WELL. “We’re proud to honor HeardThat and Singular Hearing for their work, and we know they’ll continue to gain popularity.”

For more information on HeardThat, please visit heardthat.ai.

About Singular Hearing

Singular Hearing is a subsidiary of Singular Software. Founder and CEO Bruce Sharpe and his team of AI experts have extensive experience in audio technology and a deep passion for finding effective solutions to everyday problems. They leverage machine learning and speech processing to create innovative products that help people live better by hearing better.

Singular Hearing is the creator of HeardThat, an award-winning innovative app that turns smartphones into sophisticated hearing-assistive devices. HeardThat helps those with hearing challenges by delivering clear speech in noisy environments.

HeardThat was named runner-up at the AGE-WELL National Impact Challenge 2022. The app also won the What’s Next Innovation Challenge Sponsored by AARP Innovation Labs at the 17th Annual What’s Next Longevity Venture Summit and was named the first runner-up in the What’s Next Business Plan Competition at the 17th What’s Next Longevity Venture Summit. For more information, please visit heardthat.ai.

Share article on social media or email:

Innovation Fertility Launches Reproductive Specialists of the Carolinas


Innovation Fertility, a network of leading IVF clinics and laboratories, today announced that it has partnered with a Charlotte-based reproductive endocrinologist to offer advanced fertility treatments under the name of Reproductive Specialists of the Carolinas. The new clinic is led by Dr. Matrika Johnson, a dual board-certified OB/GYN and reproductive endocrinologist recently recognized as one of Charlotte’s “Top Doctors” by Charlotte Magazine. The investment in Reproductive Specialists of the Carolinas anchors Innovation Fertility’s commitment to offering state-of-the-art reproductive services in the Charlotte market. The financial terms of the deal were not disclosed.

Reproductive endocrinology is among the fastest-growing medical specialties. Demand for advanced fertility care will continue to rise as couples are deciding to have children later in life and the prevalence of male infertility, driven by environmental and lifestyle factors, increases. Further trends favoring industry demand are a growing percentage of same-sex couples desiring children and an increasing number of employers offering benefits for IVF and genetic testing services.

“We are thrilled to have Dr. Johnson leading our Charlotte office,” explained Dwight P. Ryan, CEO of Innovation Fertility. He continued, “Dr. Johnson is incredibly passionate about helping people build families. Her extensive knowledge and her intimate, personalized approach to patient care are completely aligned with our goal of providing the most advanced treatment options and the best patient care. Together, we look forward to leading the way in innovative and patient-centric fertility care in North Carolina.”

“Working with Innovation Fertility helped me design a premiere boutique REI practice,” said Dr. Johnson. “They helped with everything from clinical and laboratory design, purchasing all equipment and providing trained staff.”

ABOUT DR. MATRIKA D. JOHNSON

Matrika D. Johnson, M.D., is board-certified in Obstetrics and Gynecology as well as Reproductive Endocrinology and Infertility. Since 2020, Dr. Johnson has appeared in Charlotte Magazine’s list of the Top Doctors in Charlotte for reproductive endocrinology and infertility.

ABOUT INNOVATION FERTILITY

Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine premier reproductive endocrinologists with laboratory operations, resulting in exceptional medical care and an unparalleled patient experience.

FORWARD-LOOKING STATEMENT

This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Reproductive Specialists of the Carolinas following its acquisition by Innovation Fertility. If any of these risks or uncertainties materialize, or if any of Reproductive Specialists of the Carolinas’ or Innovation Fertility’s assumptions prove incorrect, Reproductive Specialists of the Carolinas’ results could differ materially from the results expressed OR implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Reproductive Specialists of the Carolinas and Innovation Fertility as of the date of this communication, and Reproductive Specialists of the Carolinas and Innovation Fertility do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Share article on social media or email:

FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to Enable GMP Manufacturing of Cell and Exosome Therapies


“Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to partner with FUJIFILM Diosynth Biotechnologies to translate our MSC and exosome technologies into advanced therapy products for patients around the world.” – Tim Kelly, CEO, RoosterBio

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today a strategic collaboration with RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio’s industry-leading process development technology for both MSC and extracellular vesicle (EV) / exosome programs into its manufacturing capabilities and offerings.

This collaboration offers biopharma customers an end-to-end solution for development and production of MSC and exosome therapeutics, allowing for seamless transition of programs from RoosterBio’s process and analytical development services into FUJIFILM Diosynth Biotechnologies’ advanced therapies GMP capabilities. Manufacturing services and expertise provided by FUJIFILM Diosynth Biotechnologies will include cell expansion and collection of MSCs, downstream processing for exosome purification, and drug product manufacturing. Terms of the agreement were not disclosed.

“This collaboration will enable us to become a fully integrated cell therapy CDMO partner to our biopharma customers,” said Gerry Farrell, chief operating officer, FUJIFILM Diosynth Biotechnologies, Texas and California. “MSC products are known to have great potential in areas such as regenerative medicine and immune system modulation. In addition, exosomes are attractive as drug delivery vehicles as well as therapeutics. The partnership is aligned with our core purpose of advancing tomorrow’s medicines by enabling the advancement of our customer’s pipelines in this space.”

“FUJIFILM Diosynth Biotechnologies is a global leader in the manufacturing of advanced therapies and is creating the industry’s largest network of biologics CDMO facilities,” said Tim Kelly, chief executive officer, RoosterBio. “Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities. Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to partner with FUJIFILM Diosynth Biotechnologies to translate our MSC and exosome technologies into advanced therapy products for patients around the world.”

About RoosterBio

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year. RoosterBio is driven by clients’ success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

http://www.roosterbio.com

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. The company operates a global network with major locations in the Unites States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies’ UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites.

For more information, go to: http://www.fujifilmdiosynth.com

About FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2022, the company had global revenues of approximately 2.5 trillion yen (21 billion $USD at an exchange rate of 122 yen/dollar).

For more information, please visit: http://www.fujifilmholdings.com

Share article on social media or email:

Clean Beauty Brand Aloette Announces Party with Purpose Charity Incentive for Mental Health Awareness Month


“I am thrilled that Aloette and our entire field have come together to draw awareness and support to this very important issue,” says President of Aloette, Cathy McKenna. “We are hoping for a tremendous week so that we can really give back to our community.”



Aloette, an industry leader in providing clean beauty solutions that are gentle for skin and the environment, is announcing an exciting charity incentive for Mental Health Awareness Month. From October 23rd-October 31st, Aloette will be donating a portion of all party sales to organizations in the US and Canada that address the mental health issues that women face throughout their lifetime. Aloette says their goal is to raise awareness and help stop the stigma associated with asking for help with mental health issues.

“I am thrilled that Aloette and our entire field have come together to draw awareness and support to this very important issue,” says President of Aloette, Cathy McKenna. “We are hoping for a tremendous week so that we can really give back to our community.”

Research states that 1 in 5 women experience a common mental health disorder at least once in their lifetime. Aloette wants to be a part of the solution to expand knowledge, treatment, compassion, and understanding to those dealing with mental health issues. The beauty and skincare brand has asked both customers and consultants to help raise funds for the cause in the following ways:

Consultants: Book Aloette parties both in person and virtually to help raise funds for the cause. Consultants are encouraged to share personal stories, if comfortable, or facts related to mental health issues on social media using Aloette graphics as well as creating personal content regarding mental health.

Customers: Host a party from October 23rd-October 31st and a position of sales will be donated to the charity Aloette is supporting. As a special thank you, Aloette will be giving customers one of the new Jetsetter Palette’s for $10 for those hosting a party during the last week of October 2022.

Other ways that Aloette fans can help is by making an independent donation to the organizations Aloette supports, such as Canadian Mental Health Association (CMHA) and Seek Her Foundation in the US, or other outside mental health organizations. Aloette also encourages others to join “The Hub,” Aloette’s Facebook group, to share mental health stories with Aloette’s supportive community. Customers and consultants at Aloette agree that women are #BetterTogether regarding promoting and raising awareness for mental health struggles, and those at Aloette are excited to help stop the stigma regarding mental health.

About Aloette

Aloette is North America’s premier age-defying beauty brand, providing women of all ages and origins with the high-quality skin care and cosmetic products and home-based business opportunities in the health and beauty industry. Incorporating clean and cutting-edge cosmetic ingredients and technology, Aloette offers an array of high-performance makeup and skin care solution lines designed to help deliver real results. Aloette Cosmetics is an Astral Brands company. For more information, visit http://www.aloette.com.

Share article on social media or email:

New fertility study by Shady Grove Fertility (SGF) provides hope for those diagnosed with cancer


Shady Grove Fertility’s research team presented an award-winning study at ASRM 2022 that can provide reassurance for patients undergoing fertility preservation treatment following a cancer diagnosis.

“At SGF, we know the importance of innovative, evidence-based fertility care. With this new information, we can better counsel patients and reassure them that their cancer diagnosis does not have to mean the end of their family-building dreams.”

New research from Shady Grove Fertility (SGF), conducted with the University of Colorado School of Medicine and the School of Public Health, has shown that patients with a recent cancer diagnosis can expect comparable results from fertility preservation treatment to those who are undergoing elective egg-freezing.

Presented this week at the 78th ASRM Scientific Congress & Expo in Anaheim, California, the study was selected as the Fertility Preservation Special Interest Group Prize Paper. The study, Ovarian Response and Anti-Mullerian Hormone in Fertility Preservation Versus Elective Oocyte Cryopreservation Cycles: A Society for Assisted Reproductive Technology Registry Study of 10,040 Cycles, was conducted by Ivy Lersten, M.D., University of Colorado School of Medicine and SGF fellow; Angela J. Fought, University of Colorado School of Public Health; and Cassandra Roeca, M.D., SGF physician who sees patients at SGF Colorado’s Denver location.

This national retrospective cohort study of ovarian response and anti-Mullerian hormone (AMH) in cancer patients undergoing fertility preservation treatment compared to patients who are electively freezing their eggs looked at data from 10,040 cycles from the Society for Assisted Reproductive Technology (SART) registry and found the relationship between the number of eggs retrieved or cryopreserved and AMH did not differ for fertility preservation versus elective egg freezing groups.    

“The relationship between AMH levels and ovarian response to fertility treatment is well established,” shares Dr. Roeca. “We wanted to investigate whether this relationship is preserved for patients with a recent cancer diagnosis.”

The study concludes that the relationship between retrieved and frozen eggs, as well as AMH levels, for cancer patients undergoing fertility preservation treatment are comparable to those who are electively freezing their eggs. This new information can provide additional reassurance for patients with cancer who are planning to have biological children in the future.

“At SGF, we know the importance of innovative, evidence-based fertility care,” adds Dr. Roeca. “With this new information, we can better counsel patients and reassure them that their cancer diagnosis does not have to mean the end of their family-building dreams.”

SGF is one of only a few private practice fertility centers in the country to employ a full-time dedicated research team, which operates under Director of Research, Kate Devine, M.D., a board certified reproductive endocrinologist who sees patients at SGF’s Washington, D.C., K Street location. Dr. Devine also serves as the Executive Medical Director and Chief Research Officer at US Fertility, the largest network of physician-owned and physician-led fertility practices in the United States, of which SGF is a founding partner practice.

To best serve patients newly diagnosed with cancer, SGF works closely with patients and their cancer team to ensure that all patients interested in fertility preservation will receive an immediate consultation and best preservation options based on their cancer treatment plan.

As a premier IVF and fertility center of excellence, SGF continues to make a sustained commitment to clinical research and educating physicians in training.

To learn more about ongoing research being conducted at SGF, visit http://www.shadygrovefertility.com/research.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 50 locations, including the newest location in Raleigh, North Carolina, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Share article on social media or email: